1-3 of 3
Catherine Frelin
Close
Sort by
Journal Articles

Pharmacological Blockade of NF-kB Targets Both Imatinib-Sensitive or -Resistant Chronic Myeloid Leukemia Cells for Cell Death.

Véronique Imbert, PhD, Nadia Lounnas, Catherine Frelin, PhD, Nadège Gonthier, Emmanuel Griessinger, Nicolas Sirvent, MD, Michael Hummelberger, MD, Jil-Patrice Cassuto, MD, François-Xavier Mahon, MD, Jean-François Michiels, MD, Philippe Rousselot, MD, Michel Dreano, PhD, Jean-François Peyron, PhD
Journal: Blood
Blood (2006) 108 (11): 4793.
https://doi.org/10.1182/blood.V108.11.4793.4793
Published: 2006
Journal Articles

Pharmacological Blockade of NF-kB with AS602868, a Potent Small Molecule Inhibitor of IKK2 Leads to Apoptosis of Sensitive and Resistant Chronic Myeloid Leukemia Cells.

Veronique Imbert, PhD, Nadege Gonthier, PhD, Catherine Frelin, PhD, Nicolas Sirvent, MD, Michael Hummelsberger, MD, Anne Sirvent von Bueltzingsloewen, MD, Jill-Patrice Cassuto, MD, Francois-Xavier Mahon, MD, Philippe Rousselot, MD, Michel Dreano, PhD, Jean-Francois Peyron, PhD
Journal: Blood
Blood (2005) 106 (11): 2882.
https://doi.org/10.1182/blood.V106.11.2882.2882
Published: 2005
Journal Articles

Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells

Catherine Frelin, Véronique Imbert, Emmanuel Griessinger, Annie-Claude Peyron, Nathalie Rochet, Patrick Philip, Christian Dageville, Anne Sirvent, Michaël Hummelsberger, Etienne Bérard, Michel Dreano, Nicolas Sirvent, Jean-François Peyron
Journal: Blood
Blood (2005) 105 (2): 804–811.
https://doi.org/10.1182/blood-2004-04-1463
Published: 2005